Intravesical gemcitabine in recurrent superficial bladder carcinoma: Preliminary results on ablative efficacy and tolerability

Fabio Campodonico, Giorgio Canepa, Giacomo Capponi, Luigi Bozzo, Massimo Maffezzini

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The ablative potential and toxicity of gemcitabine, administered intravesically in low stage and grade superficial transitional cell carcinoma (TCC), were evaluated. Patients and Methods: Patients with a history of recurrent Ta-T1, G1-G2 bladder TCC were considered eligible for the study. Gemcitabine was administered intravesically at 40 mg/mL concentration (2000 mg in 50 ml saline) in one weekly instillation for 4 consecutive weeks. Fifteen days after the last instillation, patients were submitted to transurethral resection (TUR). Results: Twenty-six patients were evaluable for toxicity, and 20 were evaluable for response, 6 patients being excluded due to toxicity. A complete response was achieved by 10 out of 20 patients (50%), whereas no response was documented in the remainder. Toxicity leading to treatment interruption was grade 3 in 1 patient and grade 2 in 5 patients. Conclusion: Intravesical gemcitabine administered at 40 mg/mL showed the capability of ablating small volume, superficial TCC in 50% of the population under study, with acceptable tolerability.

Original languageEnglish
Pages (from-to)2381-2384
Number of pages4
JournalAnticancer Research
Volume25
Issue number3 C
Publication statusPublished - May 2005

Keywords

  • Gemcitabine
  • Intravesical chemotherapy
  • Superficial bladder cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Intravesical gemcitabine in recurrent superficial bladder carcinoma: Preliminary results on ablative efficacy and tolerability'. Together they form a unique fingerprint.

Cite this